Biotechnology

Beyond Biotech Podcast 15: Cullinan Oncology, Pleco, TikoMed

There are three guests on the podcast this week. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadeem Ahmed, CEO of Cullinan Oncology; a chat with Ivo Zimmermans, CEO of Pleco Therapeutics; and talk to Anders Christensen, CEO of TikoMed.

We also have our weekly chat with a global commercial real estate company JLLwith Travis McCready.

This week’s podcast sponsor Single use supportprovider of end-to-end fluid management solutions.

World Cancer Research Day: Support research aimed at preventing and detecting cancer at an early stage

For seven consecutive years, the international research community celebrates World Cancer Research Day (WCRD) on September 24, a global movement that seeks to raise awareness of the importance of cancer research to improve survival, facilitate access to scientific advances worldwide and reduce the global burden of cancer.

This year, oncology experts and cancer researchers will focus on cancer health disparities, particularly in the areas of prevention and early detection research and care. This year’s motto is “Support research to prevent cancer and detect it at an early stage.”

Cancer is a major public health problem and the second leading cause of death worldwide. The global burden of cancer continues to rise and is expected to double by 2040 compared to the number of cases in 2012. This situation calls for coordinated action that brings together all international efforts with initiatives such as the WCRD.

The international community is coming together to promote cancer research and make a global call to raise awareness of the importance of cancer research and the current challenges that need to be addressed so that advances and research results can reach patients as quickly as possible.

Cullinan Oncology

To talk about the current state of cancer research, we spoke to Nadeem Ahmed, the company’s CEO Cullinan Oncology.

Cullinan Oncology is a biopharmaceutical company dedicated to creating new standards of care for cancer patients. Through his own discoveries and collaboration with academic and industrial partners, he finds the most promising cancer treatments ready for clinical use.

Cullinan uses its small molecule and biologics science to generate differentiated ideas, identify unique targets, and select optimal pathways to develop transformative cancer therapeutics. With its new research model, Cullinan pushes the conventional boundaries from candidate selection to cancer therapy, applying early experiments to fast-track only the most promising assets into the clinic and ultimately commercialization.

As a result, the company’s pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic factors across a wide range of modalities, each with the potential to be best-in-class or first-in-class.

Pleco Therapeutics raises €17.3m to develop AML product

Pleco Therapeutics BV, a specialty biopharmaceutical company in the Netherlands developing novel therapies designed to detoxify the cancer microenvironment, has raised a total of €17.3 million ($17.2 million) in Series A funding.

The funds will be used to complete the development and commercialization of Plecoid’s new lead product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukemia (AML).

Pleco’s technology provides a platform for developing a pipeline of therapies. In addition to PTX-061 for the treatment of AML, the current pipeline includes additional candidates in preclinical trials for the treatment of other rare diseases such as SCLC.

The study shows TikoMed st ILB has potential for the treatment of neurodegenerative diseases, including ALS

Peer-reviewed studies published in Frontiers in Pharmacology supports the mechanism of the broad spectrum of action of the Swedish company Biopharma TikoMed’s ILB neuroprotective drug platform.

In numerous preclinical and clinical studies of various diseases caused by neuroinflammation, the low molecular weight compound dextran sulfate both mobilized and modulated natural tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors.

TikoMed said it believes this approach to enhancing the body’s capacity for self-healing and regeneration could change the current paradigms of cell and gene therapy.

https://www.labiotech.eu/trends-news/beyond-biotech-podcast-15-cullinan-oncology-pleco-tikomed/ Beyond Biotech Podcast 15: Cullinan Oncology, Pleco, TikoMed

Back to top button